Elixion BioTech AG

Company Bio

Elixion Biotech develops first-in-class oncology assets by targeting causal disease drivers. We have in silico validated two targets (one novel, high-upside) and are advancing towards confirmation alongside in silico drug design, positioning for early partnering in high-need cancers.